Urogen Pharma Ltd. (URGN)
UroGen Pharma: An Emerging GARP Stock
UroGen Pharma has pulled back 30% after a 208% rally, driven by Zusduri's strong launch as the only approved non-surgical LG-IR-NMIBC therapy. Zusduri's rapid uptake, favorable patient preference, and robust clinical data support continued growth, with patent protection until 2044 and 95% reimbursement coverage. URGN faces looming clinical competition but currently only contends with TURBT, positioning it for robust growth through at least 2027.
Urogen Pharma: Upside After Bladder Cancer Launch
UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance of remaining disease-free at 3 years among responders. URGN-103, a next-generation mitomycin-based product, is positioned to replace Zusduri, offering manufacturing and convenience advantages; NDA submission is complete and approval is likely.
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
The consensus price target hints at a 27.1% upside potential for Urogen Pharma (URGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Urogen Pharma Q2 Earnings Call Highlights
Urogen Pharma NASDAQ: URGN reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain traction. The company recorded a net loss of $14.4 million, or $0.28 per share, compared with a $49.9 million loss, or $1.05 per share, in the prior-year quarter.
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $1.05 per share a year ago.
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat
UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZUSDURI, driving a differentiated investment thesis. ZUSDURI revenue surged 109% sequentially to $29.2M in Q1 2026; repeat prescribers and workflow integration signal durable adoption and positive operating leverage. URGN's premium valuation is justified by a $5B+ TAM, durable clinical data, patent protection to 2044, and a de-risked pipeline including UGN-103.
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
